Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Grace Montgomery

Having built up two years knowledge of the global pharmaceutical industry, Grace reports on a wide range of topics including companies' business strategies, regulatory affairs, market research and product pipelines. Along with story sourcing, she particularly enjoys analyzing industry reports and highlighting companies' corporate business plans, and has attended industry conferences to network and attain exclusive content. Grace enjoys puzzles, baking and keeping active.
Advertisement
Set Alert for Articles By Grace Montgomery

Latest From Grace Montgomery

Aurobindo Acquires Seven Oncology Injectables From Spectrum

In line with its strategy to establish its presence in the US branded market, Aurobindo has through its subsidiary Acrotech Biopharma acquired seven marketed oncology injectables from Spectrum Pharmaceuticals in a deal worth up to US$300 million.

United States M & A

First Sabril Rival Sees FDA Deliver On Prioritizing Competition

Prioritizing the approval of generics of medicines with little or no competition has been a key part of the FDA’s efforts to support access and reduce costs to patients; the agency has just granted Teva approval for the first generic version of Lundbeck’s Sabril (vigabatrin) 500mg tablets.

Generic Drugs Approvals

Manufacturing Roundup – 17 January 2019

Dr Reddy’s is hit with a manufacturing setback after getting issued a Form 483 report for its site in Andhra Pradesh, India, while several firms announce site expansions, including in Spain and the US.

Companies Manufacturing

Switching Studies Show Safety Of Celltrion's Infliximab Biosimilar In IBD

Two infliximab switching studies have provided reassuring data on the safety of Celltrion’s CT-P13 infliximab biosimilar to treat IBD. While one report explores changing pediatric patients to CT-P13 from the Remicade reference drug, the other looks at reverse switching patients from the biosimilar to the originator brand.

Biosimilars Market Intelligence

Cipla Partners With Bio-Thera For Bevacizumab In Select Emerging Markets

Cipla has formed a licensing agreement with Bio-Thera Solutions for the Chinese firm’s BAT1706 bevacizumab biosimilar, which the Indian company will distribute and sell in select emerging markets.

Biosimilars Deals

Pfizer To Close Two Former Hospira Sites In India

Pfizer is set to close two of its manufacturing facilities in India this year, after the firm concluded that production at the former Hospira sites “is not viable” due to falling demand.

India Generic Drugs
See All
Advertisement
UsernamePublicRestriction

Register